Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences presented preclinical data for CGT1145, a novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association Congress. The data highlights >100x selectivity over wild-type JAK2 and JAK1/3 isoforms, suggesting a potential best-in-class profile with improved hematologic tolerability compared to current therapies.
Key figures
- Drug Name
- CGT1145
- Selectivity vs wt
- >100x
- Ind submission target
- 2026
- Selectivity vs jak1 3
- >100x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.